BS_T55Y4Z0Y
low-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- low-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- low-grade glioma
- age_years
- 1.016
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.549
- COAGULATION+0.525
- INTERFERON_GAMMA_RESPONSE+0.520
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.511
- INFLAMMATORY_RESPONSE+0.500
- ALLOGRAFT_REJECTION+0.476
- IL6_JAK_STAT3_SIGNALING+0.465
- MYOGENESIS+0.464
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.453
- TNFA_SIGNALING_VIA_NFKB+0.436
Top 10 suppressed
- E2F_TARGETS-0.594
- G2M_CHECKPOINT-0.548
- MYC_TARGETS_V1-0.520
- MYC_TARGETS_V2-0.283
- DNA_REPAIR-0.281
- PROTEIN_SECRETION-0.263
- MITOTIC_SPINDLE-0.234
- UNFOLDED_PROTEIN_RESPONSE-0.219
- OXIDATIVE_PHOSPHORYLATION-0.151
- SPERMATOGENESIS-0.151
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_24AHZ9ZW | low-grade glioma | — | 0.972 |
| 2 | BS_478TN841 | Ganglioglioma | — | 0.956 |
| 3 | BS_4BWB0FA0 | low-grade glioma | — | 0.954 |
| 4 | BS_EFEZB0ZH | low-grade glioma | — | 0.954 |
| 5 | BS_769BDPDB | pilocytic astrocytoma | — | 0.948 |
| 6 | MDT-AP-0384 | Med | Medulloblastoma | 0.948 |
| 7 | BS_D3YBV7KB | low-grade glioma | — | 0.947 |
| 8 | SAMN03290926 | — | — | 0.943 |
| 9 | BS_S9929Z8B | Ganglioglioma | — | 0.941 |
| 10 | s_150203_1a | EPN | Posterior Fossa EPN | 0.937 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.549 | Inavolisib | — uncovered |
| COAGULATION | 0.525 | Binimetinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.520 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.511 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.500 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.476 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.465 | Inavolisib | — uncovered |
| MYOGENESIS | 0.464 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.453 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.436 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.403 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.401 | Idelalisib | — uncovered |
| COMPLEMENT | 0.394 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.390 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.358 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.358 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.354 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.351 | Idelalisib | — uncovered |
| HYPOXIA | 0.344 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.319 | Remibrutinib | — uncovered |